[Table, Clinical Review Report]. - Glycerol Phenylbutyrate (Ravicti)

Drug	Glycerol phenylbutyrate (Ravicti)
Indication	Use as a nitrogen-binding agent for chronic management of adult and pediatric patients ≥ 2 years of age with urea cycle disorders who cannot be managed by dietary protein restriction and/or amino acid supplementation alone
Reimbursement request	As per indication
Dosage form(s)	Oral liquid, 1.1 g/mL
NOC Date	March 18, 2016
Manufacturer	Horizon Therapeutics Canada

Cover of Glycerol Phenylbutyrate (Ravicti)

Glycerol Phenylbutyrate (Ravicti) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.